02.06.2013 Views

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

(2001): Ahrendt DM, Am Fam Physician 63(5), 913<br />

(2001): Ayotte C+, Can J Appl Physiol 26(Suppl), S120<br />

(2000): Pecci MA+, Phys Med Rehabil Clin N Am 11(4), 949<br />

Coarsening of skin<br />

(1998): Med Lett <strong>Drug</strong>s Ther 40, 105<br />

Edema<br />

Seborrhea<br />

Hair<br />

Hair – alopecia<br />

(1998): Med Lett <strong>Drug</strong>s Ther 40, 105<br />

Hair – hirsutism (in women)<br />

(1999): Pheatt N, Sports Supplements. Pharmacist’s Letter 99, 1<br />

Other<br />

Gynecomastia<br />

Side effects (sic)<br />

(2002): Lawrence ME+, J Clin Gastroenterol 35(4), 299<br />

Note: The FDA has requested companies to stop distributing<br />

products containing <strong>and</strong>rostenedione. Studies have shown that it does<br />

not increase muscle mass <strong>and</strong> that it poses the same kind of health<br />

risks as anabolic steroids, including abnormal elevations in serum<br />

estrogen, increased risk of prostate, pancreatic <strong>and</strong> endometrial<br />

cancers, <strong>and</strong> increased cardiovascular disease risk<br />

ANIDULAFUNGIN<br />

Synonym: LY-303366<br />

Trade name: Eraxis (Vicuron) (Roerig/Pfizer)<br />

Indications: C<strong>and</strong>idemia, c<strong>and</strong>idal esophagitis<br />

Category: Antimycobacterial, echinoc<strong>and</strong>in<br />

Half-life: 0.5–1.0 hour<br />

Clinically important, potentially hazardous interactions<br />

with: None<br />

Reactions<br />

Skin<br />

Angioedema (

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!